Biological activity of piceatannol: leaving the shadow of resveratrol
H Piotrowska, M Kucinska, M Murias - Mutation Research/Reviews in …, 2012 - Elsevier
Resveratrol (3, 4′, 5-trans-trihydroxystilbene), a naturally occurring stilbene, is considered
to have a number of beneficial effects, including anticancer, anti-aethrogenic, anti-oxidative …
to have a number of beneficial effects, including anticancer, anti-aethrogenic, anti-oxidative …
Getting Syk: spleen tyrosine kinase as a therapeutic target
RL Geahlen - Trends in pharmacological sciences, 2014 - cell.com
Spleen tyrosine kinase (Syk) is a cytoplasmic protein tyrosine kinase well known for its
ability to couple immune cell receptors to intracellular signaling pathways that regulate …
ability to couple immune cell receptors to intracellular signaling pathways that regulate …
Pharmacometrics of stilbenes: seguing towards the clinic
KA Roupe, CM Remsberg, JA Yáñez… - Current clinical …, 2006 - ingentaconnect.com
Stilbenes are small molecular weight (∼ 200-300 g/mol), naturally occurring compounds
and are found in a wide range of plant sources, aromatherapy products, and dietary …
and are found in a wide range of plant sources, aromatherapy products, and dietary …
Ampelopsin reduces endotoxic inflammation via repressing ROS-mediated activation of PI3K/Akt/NF-κB signaling pathways
S Qi, Y Xin, Y Guo, Y Diao, X Kou, L Luo… - International …, 2012 - Elsevier
Ampelopsin (AMP), a plant flavonoid, has potent anti-inflammatory properties in vitro and in
vivo. The molecular mechanisms of ampelopsin on pharmacological and biochemical …
vivo. The molecular mechanisms of ampelopsin on pharmacological and biochemical …
Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance
A Levitzki - Annual review of pharmacology and toxicology, 2013 - annualreviews.org
With the manufacture of imatinib, researchers introduced tyrosine kinase inhibitors (TKIs)
into the clinical setting in 2000 to treat cancers; approximately fifteen other TKIs soon …
into the clinical setting in 2000 to treat cancers; approximately fifteen other TKIs soon …
The contribution of transforming growth factor-β and epidermal growth factor signalling to airway remodelling in chronic asthma
C Boxall, ST Holgate, DE Davies - European Respiratory …, 2006 - Eur Respiratory Soc
Asthma is increasing in prevalence in the developing world, affecting∼ 10% of the world's
population. It is characterised by chronic lung inflammation and airway remodelling …
population. It is characterised by chronic lung inflammation and airway remodelling …
Soy isoflavones and immunity
T Sakai, M Kogiso - The Journal of Medical Investigation, 2008 - jstage.jst.go.jp
The amount of soy products consumed in Japan is much greater than that in Western
countries. Recent evidence indicates that soy isoflavones play a beneficial role in obesity …
countries. Recent evidence indicates that soy isoflavones play a beneficial role in obesity …
Genomic and expression profiling identifies the B‐cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma
A Rinaldi, I Kwee, M Taborelli, C Largo… - British journal of …, 2006 - Wiley Online Library
Among B‐cell lymphomas mantle cell lymphoma (MCL) has the worst prognosis. By using a
combination of genomic and expression profiling (Affymetrix GeneChip Mapping 10k …
combination of genomic and expression profiling (Affymetrix GeneChip Mapping 10k …
Transcription factor NF-κB: an update on intervention strategies
The nuclear factor (NF)-κB family of transcription factors are ubiquitous and pleiotropic
molecules that regulate the expression of more than 150 genes involved in a broad range of …
molecules that regulate the expression of more than 150 genes involved in a broad range of …
Targeting non-malignant disorders with tyrosine kinase inhibitors
F Grimminger, RT Schermuly… - Nature reviews Drug …, 2010 - nature.com
Receptor and non-receptor tyrosine kinases are involved in multiple proliferative signalling
pathways. Imatinib, one of the first tyrosine kinase inhibitors (TKIs) to be approved …
pathways. Imatinib, one of the first tyrosine kinase inhibitors (TKIs) to be approved …